Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  19.00 1.35% 1,425.00 1,424.80 1,425.40 1,455.80 1,416.40 1,416.40 9,359,939 16:29:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.0 5,442.0 87.6 16.3 57,960

GlaxoSmithKline PLC Directorate Change

04/05/2022 10:00am

UK Regulatory (RNS & others)


Gsk (LSE:GSK)
Historical Stock Chart


From Feb 2022 to Aug 2022

Click Here for more Gsk Charts.

TIDMGSK

RNS Number : 2672K

GlaxoSmithKline PLC

04 May 2022

Issued: 4 May 2022, London UK - LSE announcement

GSK announces Dr Vishal Sikka to join the Board as Non-Executive Director

GlaxoSmithKline plc (LSE/NYSE: GSK) has today announced that Dr Vishal Sikka, founder and CEO of Vianai Systems, will join the Board of the Company as a Non-Executive Director. He will join the Board with effect from the Haleon demerger.

Vishal has a distinguished background in technology and particularly in the field of Artificial Intelligence (AI) and Machine Learning, which is central to GSK's approach to R&D. He is the founder and CEO of Vianai Systems, a Silicon Valley-based company that provides advanced technological software and services in AI and Machine Learning to large enterprises around the world. Prior to founding Vianai Systems, Vishal served as CEO of Infosys and as a member of the Executive Board of SAP SE. Vishal has a PhD in Artificial Intelligence from Stanford University and has co-authored several research abstracts related to AI, technology and database management. He is also currently a Board member of Oracle Corporation and BMW.

Commenting on the appointment, Sir Jonathan Symonds, Chair of GSK said: "I am delighted to welcome Vishal to GSK. He is an experienced board director and an outstanding technologist who has been at the forefront of advanced technologies such as AI and Machine Learning for decades. Harnessing and applying these technologies to the discovery and development of new medicines and vaccines is central to our R&D approach, and Vishal's insight and expertise will be invaluable as the company accelerates its efforts in this area."

Vishal's appointment further strengthens the Board's expertise and builds on other recent Non-Executive Director appointments, including Dr Harry (Hal) C. Dietz, Professor of Genetic Medicine at The Johns Hopkins University School of Medicine; Charles (Charlie) Bancroft, former Executive Vice President at Bristol Myers Squibb (BMS), and Dr Anne Beal, former instructor in paediatrics at Harvard Medical School and Massachusetts General Hospital, and Chief Patient Officer at Sanofi.

A further non-executive appointment, with deep biopharma expertise, is expected in July 2022.

Notes:

 
 1.   The appointment of Dr Vishal Sikka was made by the Board 
       on the recommendation of the Nominations & Corporate Governance 
       Committee. The Committee conducted an extensive search and 
       selection process for this appointment, using an external 
       search firm, which is a signatory of the Voluntary Code 
       of Conduct for Executive Search Firms. The external search 
       firm provided a diverse list of candidates who were approached, 
       evaluated and interviewed, against an agreed set of criteria 
       aligned to the Board's target skills matrix. 
 2.   The Board has determined that Dr Sikka will be an independent 
       Non-Executive Director on appointment in accordance with 
       the UK Corporate Governance Code. 
 3.   Dr Sikka will receive the standard basic fee for a Non-Executive 
       Director of GBP95,000 per annum. 
       (Dr Sikka will be required to invest in GSK shares in accordance 
       with the Company's shareholder approved Non Executive remuneration 
       policy.) 
 4.   Membership of other Committees will be announced in due 
       course. 
 5.   Dr Sikka does not have a service contract. He has a letter 
       of appointment which may be viewed by contacting the Company 
       Secretary at the Company's registered office. 
 6.   There are no further disclosures to be made in respect of 
       Dr Sikka's appointment under Listing Rule 9.6.13R. 
 

About GSK

GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us .

 
GSK enquiries: 
Media enquiries:  Tim Foley         +44 (0) 20 8047      (London) 
                                     5502 
                  Kathleen Quinn    +1 202 603 5003      (Washington 
                                                          DC) 
 
Analyst/Investor  Nick Stone        +44 (0) 7717 618834  (London) 
 enquiries: 
                  Sonya Ghobrial    +44 (0) 7392 784784  (Consumer) 
                  James Dodwell     +44 (0) 20 8047      (London) 
                                     2406 
                  Mick Readey       +44 (0) 7990 339653  (London) 
                  Josh Williams     +44 (0) 7385 415719  (London) 
                  Jeff McLaughlin   +1 215 751 7002      (Philadelphia) 
                  Frannie DeFranco  +1 215 751 4855      (Philadelphia) 
 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAZZGGKRDNGZZG

(END) Dow Jones Newswires

May 04, 2022 05:00 ET (09:00 GMT)

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart
ADVFN Advertorial
Your Recent History
LSE
GSK
Gsk
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220817 04:09:18